You are here: Home: Audio Program Guide: BCU 8 | 2006 Audio: BCU 8 | 2006
 
  Go to interview with Harold J Burstein, MD, PhD
Go to interview with Peter M Ravdin, MD, PhD
Go to interview with Robert Livingston, MD
Go to interview with Harry D Bear, MD, PhD
Go to Interview with Lisa Carey, MD and Jenny C Chang, MD
 

To listen to individual tracks, click the on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.
     
Harold J Burstein, MD, PhD
Assistant Professor of Medicine
Harvard Medical School
Breast Oncology Center
Dana-Farber Cancer Institute
Boston, Massachusetts		  
  Click here to download the entire interview  
Track 1 Introduction
Track 2 Clinical trials in biologically defined breast cancer subsets
Track 3 Importance of accurate and reliable tumor marker testing
Track 4 Selection of adjuvant hormonal therapy in clinical practice
Track 5 Clinical trial strategies for patients with hormone receptor-positive disease
Track 6 Clinical trials evaluating fulvestrant in combination with other agents

Track 7 Use of delayed or extended adjuvant hormonal therapy
Track 8 BIG 2-06: Adjuvant trastuzumab versus lapatinib versus the sequence or the combination
Track 9 Adjuvant and neoadjuvant studies evaluating polybiologic therapy
Track 10 Adjuvant chemotherapy/trastuzumab for patients with lower-risk early breast cancer
Track 11 Treatment approach for patients with “triple-negative” tumors
Track 12 Bevacizumab with or without chemotherapy for patients with residual tumor after preoperative chemotherapy
Track 13 Neoadjuvant clinical trial strategies and pathologic complete response as a surrogate endpoint
Track 14 Incorporation of bevacizumab into the adjuvant clinical trial setting
     
Peter M Ravdin, MD, PhD
Clinical Professor of Medicine
The University of Texas
Health Science Center at San Antonio
San Antonio, Texas		  
  Click here to download the entire interview  
Track 1 Introduction
Track 2 Overview of the Oxford trialists’ meta-analysis of randomized trials in breast cancer
Track 3 Benefit of adjuvant taxanes in the Oxford Overview analysis
Track 4 Overview data on the impact of estrogen receptor status
Track 5 Oxford Overview analysis of adjuvant hormonal therapy
Track 6 Estrogen receptor status and time course of recurrence

Track 7 Incorporation of HER2 and trastuzumab into the Adjuvant! Online computer model
Track 8 Development of biologic predictors of response to chemotherapy
Track 9 Evaluation of long-term anthracycline-associated cardiotoxicity
     
Robert Livingston, MD
Professor of Medicine, Oncology
Arizona Cancer Center
Tucson, Arizona		  
  Click here to download the entire interview  
Track 1 Introduction
Track 2 SWOG-S0012: AC followed by weekly paclitaxel (T) versus weekly doxorubicin and daily oral cyclophosphamide with G-CSF followed by T as neoadjuvant therapy
Track 3 SWOG-S0012 follow-up trial concepts under development
Track 4 Impact of ER and HER2 status on response to neoadjuvant chemotherapy in SWOG-S0012
Track 5 Incorporation of bevacizumab into the proposed follow-up trial to SWOG-S0012
Track 6 Development and clinical use of nanoparticle albumin-bound (nab) paclitaxel

Track 7 Timing of bevacizumab during neoadjuvant therapy
Track 8 Bevacizumab-associated cardiotoxicity
Track 9 Potential role of VEGF in cell survival
Track 10 Selection of adjuvant chemotherapy for younger patients with node-positive disease
Track 11 Topoisomerase II (TOPO II) amplification as a predictor of responsiveness to anthracyclines
Track 12 Adjuvant chemotherapy for patients with triple-negative, node-positive disease
Track 13 First-line therapy for patients with triple-negative metastatic breast cancer
Track 14 Use of chemotherapy and bevacizumab for patients with triple-negative disease
     
Harry D Bear, MD, PhD
Chairman, Division of Surgical Oncology
Professor of Surgery and Microbiology and Immunology
Walter Lawrence Jr Distinguished Professor in Oncology
Massey Cancer Center, Virginia Commonwealth University School of Medicine
Richmond, Virginia		  
  Click here to download the entire interview  
Track 1 Introduction
Track 2 Background and results of NSABP neoadjuvant trial B-27
Track 3 NSABP-B-27 post-hoc analysis: Benefit from docetaxel based on response to AC
Track 4 Pathologic complete response as an endpoint in NSABP-B-27
Track 5 Selection of a neoadjuvant chemotherapeutic regimen
Track 6 Postoperative treatment for patients with residual disease after neoadjuvant chemotherapy

Track 7 NSABP-B-40 neoadjuvant trial: Docetaxel alone or with capecitabine or gemcitabine before AC with or without bevacizumab
Track 8 NSABP-B-40 correlative science program
Track 9 Potential antitumor effects of bevacizumab
Track 10 Comparison of paclitaxel and docetaxel
Track 11 Sentinel lymph node biopsy for patients undergoing neoadjuvant therapy
Track 12 Proposed NSABP neoadjuvant trial evaluating AC followed by weekly paclitaxel with trastuzumab, lapatinib or the combination
Track 13 Development of the Oncotype DX™ multigene assay
Track 14 Clinical utility of the Oncotype DX assay
Track 15 Adjuvant hormonal therapy for postmenopausal patients with hormone receptor-positive disease
Track 16 Side effects and tolerability of adjuvant aromatase inhibitors versus tamoxifen
Track 17 Study of Tamoxifen and Raloxifene (STAR) for postmenopausal women at high risk for breast cancer
Track 18 Clinical trials of aromatase inhibitors for prevention or treatment of DCIS
Track 19 Historical development of trastuzumab for HER2-positive disease
     

Interview with Lisa Carey, MD and Jenny C Chang, MD

Lisa Carey, MD
Associate Professor
Hematology and Oncology Clinical Research Program
UNC Lineberger
Comprehensive Cancer Center
Chapel Hill, North Carolina

Jenny C Chang, MD
Associate Professor
Breast Center at Baylor College of Medicine
Houston, Texas

  
  Click here to download the entire interview  
Track 1 Introduction
Track 2 A molecular taxonomy of breast cancer
Track 3 Changes in molecular tumor classification over time
Track 4 Development of the intrinsic list of genes comprising the molecular portraits of breast cancer
Track 5 Biological and clinical characteristics of the five tumor subtypes
Track 6 Distribution of tumor subtypes in breast cancer

Track 7 Molecular profiles as prognostic and predictive factors
Track 8 Molecular profiles as predictors of general chemotherapy resistance or sensitivity
Track 9 Development of molecular signatures predictive of response to specific chemotherapeutic agents
Track 10 Biologic distinctions among HER2-positive tumors
Track 11 cMYC as a predictor of response to trastuzumab
Track 12 TOPO II as a predictor of response to anthracyclines
Track 13 Receptor cross talk and potential changes in ER or HER2 phenotype
Track 14 Clinical trial strategies with neoadjuvant hormonal therapy
Track 15 NSABP-B-40 neoadjuvant trial: Docetaxel alone or with capecitabine or gemcitabine before AC with or without bevacizumab
Track 16 Proposed neoadjuvant trial of paclitaxel with trastuzumab, lapatinib or the combination
Track 17 Potential synergy between trastuzumab and lapatinib
Track 18 Proposed CALGB neoadjuvant trial for patients with triple-negative disease
Track 19 Future efforts to identify patients who will or will not benefit from chemotherapy